Correlation Between I Mab and NeuroSense Therapeutics

Can any of the company-specific risk be diversified away by investing in both I Mab and NeuroSense Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining I Mab and NeuroSense Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between I Mab and NeuroSense Therapeutics Ltd, you can compare the effects of market volatilities on I Mab and NeuroSense Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in I Mab with a short position of NeuroSense Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of I Mab and NeuroSense Therapeutics.

Diversification Opportunities for I Mab and NeuroSense Therapeutics

-0.4

Correlation Coefficient

I Mab  NeuroSense Therapeutics

Very good diversification

The 3 months correlation between IMAB and NeuroSense is -0.4. Overlapping area represents the amount of risk that can be diversified away by holding I Mab and NeuroSense Therapeutics Ltd in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NeuroSense Therapeutics and I Mab is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on I Mab are associated (or correlated) with NeuroSense Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NeuroSense Therapeutics has no effect on the direction of I Mab i.e., I Mab and NeuroSense Therapeutics go up and down completely randomly.

Pair Corralation between I Mab and NeuroSense Therapeutics

Given the investment horizon of 90 days I Mab is expected to generate 145.27 times less return on investment than NeuroSense Therapeutics. But when comparing it to its historical volatility, I Mab is 6.19 times less risky than NeuroSense Therapeutics. It trades about 0.01 of its potential returns per unit of risk. NeuroSense Therapeutics Ltd is currently generating about 0.2 of returns per unit of risk over similar time horizon. If you would invest  16.00  in NeuroSense Therapeutics Ltd on September 16, 2024 and sell it today you would earn a total of  9.00  from holding NeuroSense Therapeutics Ltd or generate 56.25% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	52.31%
Values	Daily Returns

I Mab  vs.  NeuroSense Therapeutics Ltd

I Mab

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days I Mab has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, I Mab is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

NeuroSense Therapeutics

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in NeuroSense Therapeutics Ltd are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, NeuroSense Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with I Mab and NeuroSense Therapeutics

The main advantage of trading using opposite I Mab and NeuroSense Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if I Mab position performs unexpectedly, NeuroSense Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeuroSense Therapeutics will offset losses from the drop in NeuroSense Therapeutics' long position.

The idea behind I Mab and NeuroSense Therapeutics Ltd pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.